How Prior Testing Impacts Misinformation Processing: A Dual-Task Approach

Research suggests that testing prior to the presentation of misinformation influences how that misinformation is processed. The present study examined the relationship between testing, the demands of misinformation narrative processing, and memory for original and post-event information. Using response latencies to a secondary task, we tested whether prior testing influenced the available resources for secondary task processing. Additionally, we investigated whether changes in narrative processing were specific to critical details tested earlier. Participants engaged in an eyewitness memory paradigm in which half were tested prior to receiving the post-event narrative. Participants responded to the secondary task at specified time points during the narrative. All participants took a final memory test after listening to the post-event narrative. We found that testing interacted with the placement of the secondary task. When responding on the secondary task was closely linked to the presentation of previously tested critical details in the narrative, retrieval-enhanced suggestibility was reduced on tests of event memory (Experiment 1) and increased post-event information learning was revealed on tests of narrative memory (Experiment 2)

When to look at maps in navigation: metacognitive control in environment learning

Abstract People learn environments through direct experience with the environment and/or through map study. Further, the different perspectives taken while learning an environment influence the knowledge acquired. After all, different information about an environment is readily available through route (e.g. by navigation) and survey (e.g. with maps) perspectives. Having a choice between direct experience and map use, or between different perspectives, suggests a role of metacognitive control in environment learning. That is, when in a new environment, learners may exercise metacognitive control by selectively choosing and implementing specific learning strategies, such as switching between perspectives. Strategy choice may depend on specific constraints, such as perspective, range of view, or amount of time to learn (to name a few). For example, people may check a map (e.g. on smartphones or GPS devices) to complement developing route knowledge. The present review discusses the role of metacognition in environment learning and outlines new directions for research to bridge these fields by examining how strategic metacognitive control over perspective switching affects environment learning. Such explorations can inform real-world environment learning and navigational aids design

Supplemental material for Characteristics associated with lack of HIV testing during pregnancy and delivery in 36 U.S. states, 2004–2013

<p>Supplemental material for Characteristics associated with lack of HIV testing during pregnancy and delivery in 36 U.S. states, 2004–2013 by Emilia H Koumans, Ayanna Harrison, L Duane House, Kim Burley, Nan Ruffo, Ruben Smith, Lauren FitzHarris, Christopher H Johnson, Allan W Taylor and Steven R Nesheim in International Journal of STD & AIDS</p

Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial

Although nitric oxide based therapeutics have been shown in preclinical models to reduce vaso-occlusive events and improve cardiovascular function, a clinical trial of a phosphodiesterase 5 inhibitor increased rates of admission to hospital for pain. We aimed to examine if riociguat, a direct stimulator of the nitric oxide receptor soluble guanylate cyclase, causes similar increases in vaso-occlusive events. This was a phase 1-2, randomised, double blind, placebo-controlled trial. Eligible patients were 18 years or older, had confirmed sickle cell disease documented by haemoglobin electrophoresis or HPLC fractionation (haemoglobin SS, SC, Sβ-thalassemia, SD, or SO-Arab), and stage 1 hypertension or proteinuria. Participants were randomly assigned 1:1 to receive either riociguat or matching placebo via a web-based system to maintain allocation concealment. Both treatments were administered orally starting at 1·0 mg three times a day up to 2·5 mg three times a day (highest tolerated dose) for 12 weeks. Dose escalation by 0·5 mg was considered every 2 weeks if systolic blood pressure was greater than 95 mm Hg and the participant had no signs of hypotension; otherwise, the last dose was maintained. The primary outcome was the proportion of participants who had at least one adjudicated treatment-emergent serious adverse event. The analysis was performed by the intention-to-treat. This trial is registered with ClinicalTrials.gov (NCT02633397) and was completed. Between April 11, 2017, and Dec 31, 2021, 165 participants were screened and consented to be enrolled into the study. Of these, 130 participants were randomly assigned to either riociguat (n=66) or placebo (n=64). The proportion of participants with at least one treatment-emergent serious adverse event was 22·7% (n=15) in the riociguat group and 31·3% (n=20) in the placebo group (difference -8·5% [90% CI -21·4 to 4·5]; p=0·19). A similar pattern emerged in other key safety outcomes, sickle cell related vaso-occlusive events (16·7 [n=11] vs 21·9% [n=14]; difference -5·2% [-17·2 to 6·5]; p=0·42), mean pain severity (3·18 vs 3·32; adjusted mean difference -0·14 [-0·70 to 0·42]; p=0·69), and pain interference (3·15 vs 3·12; 0·04 [-0·62 to 0·69]; p=0·93) at 12 weeks were similar between groups. Regarding the key clinical efficacy endpoints, participants taking riociguat had a blood pressure of -8·20 mm Hg (-10·48 to -5·91) compared with -1·24 (-3·58 to 1·10) in those taking placebo (-6·96 mm Hg (90% CI -10·22 to -3·69; p<0·001). Riociguat was safe and had a significant haemodynamic effect on systemic blood pressure. The results of this study provide measures of effect and variability that will inform power calculations for future trials. Bayer Pharmaceuticals